- Home
- ARQT
as 03-25-2025 12:30pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $18.80 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.99 - $17.75 | Next Earning Date: | 05-13-2025 |
| Revenue: | $196,542,000 | Revenue Growth: | 229.74% |
| Revenue Growth (this year): | 56.6% | Revenue Growth (next year): | 43.62% |
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Watanabe Todd Franklin | ARQT | See Remarks | Mar 17 '25 | Sell | $17.61 | 1,200 | $21,137.04 | 928,914 | |
| Burnett Patrick | ARQT | See Remarks | Mar 13 '25 | Sell | $15.04 | 61,403 | $920,510.48 | 121,936 | |
| Welgus Howard G. | ARQT | Director | Mar 3 '25 | Sell | $13.00 | 10,000 | $130,048.00 | 131,944 | |
| Matsuda Masaru | ARQT | See Remarks | Feb 28 '25 | Sell | $13.03 | 3,263 | $42,520.48 | 209,429 | |
| Burnett Patrick | ARQT | See Remarks | Feb 28 '25 | Sell | $13.16 | 3,773 | $49,407.70 | 121,936 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Feb 28 '25 | Sell | $13.16 | 25,015 | $327,019.12 | 928,914 | |
| Matsuda Masaru | ARQT | See Remarks | Feb 3 '25 | Sell | $12.70 | 8,338 | $105,892.60 | 209,429 | |
| Burnett Patrick | ARQT | See Remarks | Feb 3 '25 | Sell | $12.70 | 12,116 | $153,873.20 | 121,936 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Feb 3 '25 | Sell | $12.70 | 19,301 | $245,122.70 | 928,914 | |
| Edwards Larry Todd | ARQT | See Remarks | Feb 3 '25 | Sell | $12.70 | 2,173 | $27,597.10 | 135,555 |
Latest Arcutis Biotherapeutics Inc. News
ARQT Breaking Stock News: Dive into ARQT Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Arcutis Biotherapeutics Unit Gets Health Canada Approval for Atopic Dermatitis Treatment
CNW Group
8 days ago
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age
Zacks
13 days ago
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
GlobeNewswire
18 days ago
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
Zacks
19 days ago
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average
GlobeNewswire
20 days ago
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
20 days ago
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
GlobeNewswire
25 days ago
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
Compare ARQT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.